• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Tivantinib for advanced hepatocellular carcinoma: is MET still a viable target?

作者信息

Weekes Colin D, Clark Jeffrey W, Zhu Andrew X

机构信息

Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA 02114, USA.

Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA 02114, USA.

出版信息

Lancet Oncol. 2018 May;19(5):591-592. doi: 10.1016/S1470-2045(18)30249-3. Epub 2018 Apr 3.

DOI:10.1016/S1470-2045(18)30249-3
PMID:29625880
Abstract
摘要

相似文献

1
Tivantinib for advanced hepatocellular carcinoma: is MET still a viable target?替万替尼用于晚期肝细胞癌：MET 仍然是一个可行的靶点吗？
Lancet Oncol. 2018 May;19(5):591-592. doi: 10.1016/S1470-2045(18)30249-3. Epub 2018 Apr 3.
2
Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study.替沃扎尼（Tivantinib）二线治疗晚期肝细胞癌的随机、安慰剂对照 2 期研究。
Lancet Oncol. 2013 Jan;14(1):55-63. doi: 10.1016/S1470-2045(12)70490-4. Epub 2012 Nov 20.
3
Tivantinib: critical review with a focus on hepatocellular carcinoma.替凡替尼：聚焦肝细胞癌的批判性综述
Expert Opin Investig Drugs. 2014 Nov;23(11):1563-74. doi: 10.1517/13543784.2014.949339.
4
Tivantinib in hepatocellular carcinoma.替沃扎尼在肝细胞癌中的应用。
Expert Opin Investig Drugs. 2013 Jan;22(1):141-7. doi: 10.1517/13543784.2013.741586. Epub 2012 Nov 21.
5
The effectiveness of tivantinib for MET-high hepatocellular carcinoma: A protocol for meta analysis.替沃扎尼治疗 MET 高表达肝细胞癌的疗效：一项荟萃分析方案。
Medicine (Baltimore). 2023 Apr 21;102(16):e32591. doi: 10.1097/MD.0000000000032591.
6
Tivantinib induces G2/M arrest and apoptosis by disrupting tubulin polymerization in hepatocellular carcinoma.替万替尼通过破坏肝细胞癌中的微管蛋白聚合来诱导G2/M期阻滞和细胞凋亡。
J Exp Clin Cancer Res. 2015 Oct 12;34:118. doi: 10.1186/s13046-015-0238-2.
7
Tivantinib (ARQ197) in hepatocellular carcinoma.替凡替尼（ARQ197）用于肝细胞癌的治疗
Expert Rev Anticancer Ther. 2015 Jun;15(6):615-22. doi: 10.1586/14737140.2015.1050383.
8
Tivantinib, a new option for second-line treatment of advanced hepatocellular carcinoma? The experience of Italian centers.替万替尼，晚期肝细胞癌二线治疗的新选择？意大利中心的经验。
Tumori. 2015 Mar-Apr;101(2):139-43. doi: 10.5301/tj.5000217. Epub 2015 Mar 25.
9
Tivantinib for the treatment of hepatocellular carcinoma.替凡替尼用于治疗肝细胞癌。
Expert Opin Pharmacother. 2017 May;18(7):727-733. doi: 10.1080/14656566.2017.1316376. Epub 2017 Apr 17.
10
Tivantinib: a new promising mesenchymal-epithelial transition factor inhibitor in the treatment of hepatocellular carcinoma.替沃扎尼布：一种新型有前途的间充质-上皮转化因子抑制剂，用于治疗肝细胞癌。
Future Oncol. 2013 Feb;9(2):153-65. doi: 10.2217/fon.12.188.

引用本文的文献

1
MET promotes hepatocellular carcinoma development through the promotion of TRIB3-mediated FOXO1 degradation.MET通过促进TRIB3介导的FOXO1降解来促进肝细胞癌的发展。
Clin Mol Hepatol. 2025 Jul;31(3):1032-1057. doi: 10.3350/cmh.2024.1163. Epub 2025 Apr 11.
2
Selective Inhibitor of the c-Met Receptor Tyrosine Kinase in Advanced Hepatocellular Carcinoma: No Beneficial Effect With the Use of Tivantinib?c-Met 受体酪氨酸激酶选择性抑制剂治疗晚期肝细胞癌：替沃扎尼（Tivantinib）无效？
Front Immunol. 2021 Nov 2;12:731527. doi: 10.3389/fimmu.2021.731527. eCollection 2021.
3
MET canonical transcript expression is a predictive biomarker for chemo-sensitivity to MET-inhibitors in hepatocellular carcinoma cell lines.
MET 规范转录本表达是预测肝癌细胞系对 MET 抑制剂化疗敏感性的生物标志物。
J Cancer Res Clin Oncol. 2021 Jan;147(1):167-175. doi: 10.1007/s00432-020-03395-4. Epub 2020 Sep 26.
4
Erlotinib plus tivantinib versus erlotinib alone in patients with previously treated stage IIIb/IV non-small-cell lung cancer: A meta-analysis based on randomized controlled trials.厄洛替尼联合替凡替尼与单用厄洛替尼治疗既往治疗过的Ⅲb/Ⅳ期非小细胞肺癌患者的疗效比较：一项基于随机对照试验的荟萃分析
Medicine (Baltimore). 2020 Jun 19;99(25):e20596. doi: 10.1097/MD.0000000000020596.
5
Emerging agents and regimens for hepatocellular carcinoma.新兴的肝癌治疗药物和方案。
J Hematol Oncol. 2019 Oct 26;12(1):110. doi: 10.1186/s13045-019-0794-6.
6
Tivantinib Hampers the Proliferation of Glioblastoma Cells via PI3K/Akt/Mammalian Target of Rapamycin (mTOR) Signaling.替沃扎尼抑制胶质母细胞瘤细胞增殖的作用机制与 PI3K/Akt/哺乳动物雷帕霉素靶蛋白（mTOR）信号通路有关。
Med Sci Monit. 2019 Oct 2;25:7383-7390. doi: 10.12659/MSM.919319.
7
ARQ-197 enhances the antitumor effect of sorafenib in hepatocellular carcinoma cells via decelerating its intracellular clearance.ARQ-197通过减缓索拉非尼在肝癌细胞内的清除来增强其抗肿瘤作用。
Onco Targets Ther. 2019 Feb 26;12:1629-1640. doi: 10.2147/OTT.S196713. eCollection 2019.
8
Targeting c-MET by Tivantinib through synergistic activation of JNK/c-jun pathway in cholangiocarcinoma.通过 JNK/c-jun 通路协同激活 Tivantinib 靶向胆管癌中的 c-MET。
Cell Death Dis. 2019 Mar 8;10(3):231. doi: 10.1038/s41419-019-1460-1.
9
New Development of Biomarkers for Gastrointestinal Cancers: From Neoplastic Cells to Tumor Microenvironment.胃肠道癌症生物标志物的新进展：从肿瘤细胞到肿瘤微环境
Biomedicines. 2018 Aug 13;6(3):87. doi: 10.3390/biomedicines6030087.